AIM: The purpose of the present study was to analyze hepatic toxicity following radiotherapy combined with regional chemotherapy for hepatocellular carcinoma (HCC). METHODS: From 2001 to 2003, a total of 132 patients with HCC received 3-D conformal radiation therapy (3D-CRT) combined with chemotherapy. Patients were divided into two groups based on drug localization: the transcatheter arterial chemoembolization (TACE) group, where the chemotherapeutic drug (adriamycin) was localized within the tumor, and the non-TACE group, where the drugs (adriamycin, cisplatin, 5-fluorouracil) were diffusely spread over the entire liver. RESULTS: Patients were evaluated by biochemical parameters for any hepatic toxicity prior to, during, and until 12 months after 3D-CRT. Hepatic toxicity was defined as radiation-induced liver disease (RILD) or combined modality-induced liver disease (CMILD), which is defined as RILD with abnormal elevation of total bilirubin levels. In the TACE group, three patients developed RILD (5.6%) and none developed CMILD. In the non-TACE group, three patients (3.7%) and seven patients (8.8%) developed RILD and CMILD, respectively. CONCLUSION: Hepatic toxicity following radiotherapy combined with regional chemotherapy for HCC might be influenced by the distribution of the chemotherapeutic drugs. A more precise understanding of hepatic toxicity from chemoradiotherapy will help design optimal treatments for HCC.
AIM: The purpose of the present study was to analyze hepatic toxicity following radiotherapy combined with regional chemotherapy for hepatocellular carcinoma (HCC). METHODS: From 2001 to 2003, a total of 132 patients with HCC received 3-D conformal radiation therapy (3D-CRT) combined with chemotherapy. Patients were divided into two groups based on drug localization: the transcatheter arterial chemoembolization (TACE) group, where the chemotherapeutic drug (adriamycin) was localized within the tumor, and the non-TACE group, where the drugs (adriamycin, cisplatin, 5-fluorouracil) were diffusely spread over the entire liver. RESULTS:Patients were evaluated by biochemical parameters for any hepatic toxicity prior to, during, and until 12 months after 3D-CRT. Hepatic toxicity was defined as radiation-induced liver disease (RILD) or combined modality-induced liver disease (CMILD), which is defined as RILD with abnormal elevation of total bilirubin levels. In the TACE group, three patients developed RILD (5.6%) and none developed CMILD. In the non-TACE group, three patients (3.7%) and seven patients (8.8%) developed RILD and CMILD, respectively. CONCLUSION:Hepatic toxicity following radiotherapy combined with regional chemotherapy for HCC might be influenced by the distribution of the chemotherapeutic drugs. A more precise understanding of hepatic toxicity from chemoradiotherapy will help design optimal treatments for HCC.
Authors: Gesa Martius; Salamah Mohammad Alwahsh; Margret Rave-Fränk; Clemens Friedrich Hess; Hans Christiansen; Giuliano Ramadori; Ihtzaz Ahmed Malik Journal: Int J Clin Exp Pathol Date: 2014-07-15
Authors: Gesa Martius; Silke Cameron; Margret Rave-Fränk; Clemens F Hess; Hendrik A Wolff; Ihtzaz A Malik Journal: Int J Mol Sci Date: 2015-03-02 Impact factor: 5.923
Authors: Diego A S Toesca; Bulat Ibragimov; Amanda J Koong; Lei Xing; Albert C Koong; Daniel T Chang Journal: J Radiat Res Date: 2018-03-01 Impact factor: 2.724
Authors: Carole Massabeau; Virginie Marchand; Sofia Zefkili; Vincent Servois; François Campana; Philippe Giraud Journal: Case Reports Hepatol Date: 2011-09-15
Authors: Naila Naz; Shakil Ahmad; Silke Cameron; Federico Moriconi; Margret Rave-Fränk; Hans Christiansen; Clemens Friedrich Hess; Giuliano Ramadori; Ihtzaz A Malik Journal: Biomed Res Int Date: 2013-12-12 Impact factor: 3.411